Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Arlene O. Siefker-Radtke,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert A. Huddart,Earle F. Burgess,Mark T. Fleming,Arash Rezazadeh Kalebasty,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,Keqin Qi,Sydney Akapame,Spyros Triantos,Anne O'Hagan,Yohann Loriot

European Urology Open Science（2023）

引用 0|浏览29

暂无评分

摘要

Identification of select treatment-emergent adverse events (TEAEs) and appropriate management with dose modification and concomitant therapies result in the resolution of the majority of TEAEs. This may prevent treatment discontinuation, ensuring maximum benefit with erdafitinib.

查看译文

关键词

Erdafitinib,Fibroblast growth factor inhibitor,Toxicity,Urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要